New drug duo aims to tame Hard-to-Treat blood cancer
Disease control
Recruiting now
This study tests whether combining two medicines, mezigdomide and elranatamab, can shrink tumors or slow disease in people with multiple myeloma that has come back or stopped responding to other treatments. About 75 adults will take part. The goal is to see how many patients achi…
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated May 17, 2026 07:36 UTC